Emma Tinsley
Co-founder & CEO

Emma Tinsley is Co-founder and CEO of Weatherden. She has spent her career focused on a single question: why do the majority of clinical trials fail, and how much can this be improved?

​

Her work centers on redefining how risk and uncertainty are understood in drug development, using data-driven, repeatable approaches to separate, quantify, and actively manage both - enabling better decisions at every stage of development. She works closely with biotech and investors to design and execute strategies that increase the probability of success and deliver strong, risk-adjusted returns.

​

Emma has particular experience in asset strategy, indication selection, and structuring development pathways to unlock value efficiently with a focus on identifying the highest-value opportunities early. Her approach is grounded in the belief that outcomes in drug development are driven primarily by the quality of decisions, not the amount of capital deployed.

​

Prior to founding Weatherden, she worked in venture creation and life sciences investing at SV Health Investors, where she helped build multiple biotech companies from inception.